Karyopharm Therapeutics Inc. Earnings Per Share Diluted

Quick Answer

Karyopharm Therapeutics Inc. reported Earnings Per Share Diluted of $17.93 (loss) per share for the year ending 2025.

  • Karyopharm Therapeutics Inc. showed a decrease of -28.1% in Earnings Per Share Diluted from 2024 to 2025.
  • This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Karyopharm Therapeutics Inc.'s Earnings Per Share Diluted has declined by 559.2%.
  • Historical annual values: Fiscal year 2025: $17.93 (loss) per share | Fiscal year 2024: $14.00 (loss) per share | Fiscal year 2023: $18.79 (loss) per share | Fiscal year 2022: $2.02 (loss) per share | Fiscal year 2021: $1.65 (loss) per share | Fiscal year 2020: $2.72 (loss) per share.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: